{"entity":{"id":"invoke-bio","kind":"company","name":"Invoke Bio","aka":[],"tldr":"Invoke Bio designs personalised neoantigen vaccines in whatever form suits the patient, peptide, DNA or mRNA, using a prediction engine it says picks tumour targets with three times the accuracy of industry baselines.","summary":"Invoke Bio's immunogenicity prediction engine identifies tumour neoantigens for personalised vaccines and is modality-agnostic, supporting peptide, DNA and mRNA formats. Future of Cancer Care Today lists it as patient-orderable.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://invoke.bio/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"biotech","website":"https://invoke.bio/","stage":"startup","investors":[],"funding":[]},"route":"/companies/invoke-bio/","neighbours":{"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}]}}